Publications by authors named "Loic Meudec"
Article Synopsis
- The study aimed to assess how stopping JAK1/2 inhibitors (JAKinibs) affects the JAK/STAT signaling pathway in systemic rheumatic diseases, particularly in patients with rheumatoid arthritis.
- Researchers conducted experiments in the lab and on patients, demonstrating that Type I JAKinibs (like ruxolitinib and baricitinib) lead to significant increases in certain signaling proteins when administered, but show a rapid increase of these proteins after the drugs are stopped.
- The findings suggest that withdrawing Type I JAKinibs can lead to heightened inflammatory responses and may contribute to serious cardiac issues, while Type II JAKinibs do not have these effects.
Objective: Although airway disease associated with Sjögren's disease (Sjo-AD) is common, it is poorly studied compared with interstitial lung disease (ILD). In this study, we aimed to assess factors associated with Sjo-AD, the characteristics and prognosis of this manifestation.
Methods: We performed a retrospective multicentric study involving nine centres.
Objective: Janus kinase inhibitors (JAKi) are efficacious in RA but concerns regarding the risk of cancer associated with their exposure have recently emerged. Given the role of NK cells in antitumour response, we investigated the impact of JAKi [tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA) and filgotinib (FIL)] on NK cells.
Methods: We first performed an ex vivo phenotype of NK cells in RA patients treated with TOFA, BARI or MTX.